How much does Wegovy cost in 2026? Every price pathway explained

The retail price vs. what you actually pay

Wegovy's list price at a retail pharmacy without any program is approximately $1,350 a month — close to $16,000 a year. That number gets cited a lot and is almost universally not what people actually pay. It represents what you'd pay if you walked into a pharmacy, handed over a prescription, and had no insurance, no NovoCare program, and no coupon. For most women who proactively seek Wegovy, the real price is substantially lower.

Understanding which pathway applies to you takes about ten minutes and determines whether Wegovy costs you $25 a month or $1,350.

The cheapest pathway: commercial insurance + NovoCare savings card

If your commercial health insurance covers Wegovy and you enroll in the NovoCare savings card, your monthly out-of-pocket is capped at $25 a month. This is the most favorable Wegovy price available, and it's accessible to anyone with qualifying commercial insurance (not Medicare, Medicaid, or government insurance).

Getting to the savings card requires two things first: insurance coverage for Wegovy (which requires prior authorization, the right BMI, and often documented comorbidities), and a pharmacy in the NovoCare network. The $25 cap is a manufacturer subsidy that doesn't count toward your deductible in many plans — worth confirming with your insurer.

• Eligibility: commercial insurance with Wegovy covered; not Medicare, Medicaid, or CHIP.
• How to enroll: through NovoCare's website or at the point of sale at a participating pharmacy.
• If you're denied coverage: appeal with a physician letter citing BMI, comorbidities, and previous lifestyle treatment. Many initial denials reverse on the first appeal.
• Annual maximums: check whether the savings card has an annual cap or monthly limit, as terms can change.

Without insurance: NovoCare self-pay at $199 → $349/mo

For women without insurance coverage for Wegovy, Novo Nordisk's NovoCare self-pay program is the best brand-name option. The introductory rate is $199 a month — well below the retail price or GoodRx range. After the initial period (confirm the current duration with NovoCare directly), the ongoing price is $349 a month. This covers FDA-approved Wegovy dispensed through the NovoCare pharmacy and shipped to you.

At $349 a month ongoing, this costs roughly $4,188 a year — a real expense, but less than half of the retail pharmacy price. It also comes with NovoCare's support infrastructure and is an official Novo Nordisk program rather than a third-party coupon.

GoodRx: better than retail, worse than NovoCare

GoodRx coupons for Wegovy typically produce prices in the $300–$500 a month range depending on the pharmacy, your location, and the dose. This is a meaningful discount from retail but is more expensive than the NovoCare self-pay program for most scenarios. GoodRx coupons cannot be used with insurance — you use one or the other.

GoodRx is most useful if you already have a prescription, need to fill it now, and want the best available cash price at your local pharmacy. Pull the current price for your specific dose and your three nearest pharmacies before paying — variation between pharmacies on GoodRx can be $50–$100 a month for the same drug.

Compounded semaglutide: cheaper than Wegovy, not FDA-approved Wegovy

Compounded semaglutide through a telehealth provider — Fridays, Mochi Health, Henry Meds, and others — starts around $150 a month all-in for the starter dose. This is the same active molecule as Wegovy, produced by a 503A compounding pharmacy. It is not FDA-approved Wegovy; it lacks Novo Nordisk's manufacturing oversight and finished-product approval.

For women who want the lowest possible monthly cost and are comfortable with compounded medication and its legal framework, this is the cheapest semaglutide available. For women who want brand-name, FDA-approved Wegovy specifically, the NovoCare self-pay program is the better-value brand pathway.

Medicare and Wegovy: a changing picture

Medicare traditionally excluded weight-loss drugs from Part D coverage. The SELECT trial changed the Wegovy coverage picture: by demonstrating that semaglutide reduces major cardiovascular events (heart attack, stroke, cardiovascular death) in patients with established cardiovascular disease, it created a cardiovascular indication that some Medicare Part D plans now cover. If you're on Medicare and have a documented history of cardiovascular disease, ask your prescribing doctor to use the cardiovascular indication on the prescription. Coverage varies by plan.

Annual cost by pathway

• Commercial insurance + NovoCare savings card ($25/mo): $300/year — lowest possible pathway.
• NovoCare self-pay ongoing ($349/mo): ~$4,188/year.
• GoodRx at retail pharmacy (~$400/mo midpoint): ~$4,800/year.
• Compounded semaglutide, Fridays ($150–$249/mo): ~$1,800–$2,988/year depending on dose.
• Mochi Health all-in (~$178/mo): ~$2,136/year.
• Retail, no discount (~$1,350/mo): ~$16,200/year.